MACSprep™ Multiple Myeloma CD138 MicroBeads, human

MACSprep Multiple Myeloma CD138 MicroBeads have been developed for the positive selection of CD138+ cells directly from anticoagulated whole blood or bone marrow by using the autoMACS® Pro Separator or manual separators without additional density gradient centrifugation nor erythrocyte lysis. The purified CD138+ cells are well suited for further flow cytometry, functional, or molecular analysis such as FISH, PCR, sequencing, microarrays, and protein analysis.

qualityAssuranceSatisfaction
guaranteed
more »
Product data and images for MACSprep™ Multiple Myeloma CD138 MicroBeads, human
Figure 1

Separation of a bone marrow sample using MACSprep™ Multiple Myeloma CD138 MicroBeads and the autoMACS® Pro Separator. Cells were fluorescently stained with CD138-APC, CD38-FITC, and CD45-VioBlue® and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Specifications for MACSprep™ Multiple Myeloma CD138 MicroBeads, human
Overview

MACSprep Multiple Myeloma CD138 MicroBeads have been developed for the positive selection of CD138+ cells directly from anticoagulated whole blood or bone marrow by using the autoMACS® Pro Separator or manual separators without additional density gradient centrifugation nor erythrocyte lysis. The purified CD138+ cells are well suited for further flow cytometry, functional, or molecular analysis such as FISH, PCR, sequencing, microarrays, and protein analysis.

Citations for MACSprep™ Multiple Myeloma CD138 MicroBeads, human
Publications
  1. Sato, T. et al. (2019) DPP8 is a novel therapeutic target for multiple myeloma. Sci Rep 9 (1): 18094
  2. Isa, R. et al. (2022) The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma. Int J Mol Sci 23 (6): 2919

You have previously chosen International as your location.
What do you want to do?